The effect of weight loss on serum ceruloplasmin levels in obese patients
DOI:
https://doi.org/10.15584/ejcem.2023.2.5Keywords:
ceruloplasmin, obesity, weight lossAbstract
Introduction and aim. Serum ceruloplasmin level may be a biomarker associated with obesity and cardiovascular risk. We aimed to evaluate the effect of body weight lost by diet and exercise program on metabolic parameters and serum ceruloplasmin levels in obese patients.
Material and methods. A total of 120 obese patients with BMI ≥30 kg/m2 were enrolled in a 16-week balanced diet program with the goal of losing 10% or more of body weight while maintaining a daily energy deficit of 500-1000 kcal/day.
Results. Mean weights of the patients decreased from 93.2±15.1 kg to 83.2±13.1 kg (p<0.001) and mean BMI decreased from 35.8±5.6 kg/m2 to 31.9±4.9 kg/m2 (p<0.001). Mean ceruloplasmin decreased from 25.2±4.7 mg/dL to 23.6±4.9 mg/dL (p<0.001), mean total cholesterol from 191.8±37.1 mg/dL to 153.8±28.7 mg/dL (p<0.001), mean LDL from 120.3±31.4 mg/dL to 91.1±27.7 mg/dL (p<0.001) and mean fasting blood glucose from 108.2±35 mg/dL to 103.3±81.1 mg/dL (p<0.001). There was a statistically significant and weak correlation between the change in ceruloplasmin and the change in BMI (p=0.016, R=0.233). There was a statistically significant and weak correlation between ceruloplasmin change and weight change (p=0.010, R=0.251).
Conclusion. Obese patients’ serum ceruloplasmin levels were found to decrease with weight loss.
Downloads
References
Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007;356(3):213-215. doi:10.1056/NEJMp068177
Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402-424. doi: 10.1159/000442721
Sonnett TE, Levien TL, Gates BJ, Robinson JD, Campbell RK. Diabetes mellitus, inflammation, obesity: proposed treatment pathways for current and future therapies. Ann Pharmacother. 2010;44(4):701-711. doi: 10.1345/aph.1M640
Bouchard L, Rabasa-Lhoret R, Faraj M, et al. Differential epigenomic and transcriptomic responses in subcutaneous adipose tissue between low and high responders to caloric restriction. Am J Clin Nutr. 2010;91(2):309-320. doi: 10.3945/ajcn.2009.28085
Kawai, T, Autieri, MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375-C391. doi: 10.1152/ajpcell.00379.2020.
Pararasa C, Bailey CJ, Griffiths HR. Ageing, adipose tissue, fatty acids and inflammation. Biogerontology. 2015;16(2):235-248. doi: 10.1007/s10522-014-9536-x
Engström G, Hedblad B, Stavenow L, et al. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler Thromb Vasc Biol. 2004;24(8):1498-1502. doi: 10.1161/01.ATV.0000134293.31512.be
Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol. 2008;22(5):1023-1031. doi: 10.1210/me.2007-0529
Lind P, Hedblad B, Stavenow L, Janzon L, Eriksson KF, Lindgärde F. Influence of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. Arterioscler Thromb Vasc Biol. 2001;21(3):452-458. doi: 10.1161/01.atv.21.3.452
Macintyre G, Gutfreund KS, Martin WR, Camicioli R, Cox DW. Value of an enzymatic assay for the determination of serum ceruloplasmin. J Lab Clin Med. 2004;144(6):294-301. doi: 10.1016/j.lab.2004.08.005
Kim OY, Shin MJ, Moon J, Chung JH. Plasma ceruloplasmin as a biomarker for obesity: a proteomic approach. Clin Biochem. 2011;44(5-6):351-356. doi: 10.1016/j.clinbiochem.2011.01.014
Jakubiak GK, Osadnik K, Lejawa M, Kasperczyk S, Osadnik, Pawlas N. Oxidative stress in association with metabolic health and obesity in young adults. Oxid Med Cell Longev. 2021;2021:9987352. doi. org/10.1155/2021/9987352
WHO. Global status report on noncommunicable diseases 2014: World Health Organization; 2014.
Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation. 2010;122(4):406-441. doi: 10.1161/CIR.0b013e3181e8edf1
Poobalan A, Aucott L, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term lipid outcomes--a systematic review. Obes Rev. 2004;5(1):43-50. doi:10.1111/j.1467-789x.2004.00127.x
Tucker M. New AACE algorithm addresses all aspects of type 2 diabetes. Medscape Medical News. 2013.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327-336. doi: 10.4158/endp.19.2.a38267720403k242
Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486. doi: 10.2337/dc10-2415
Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154. doi: 10.1056/NEJMoa1212914
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867. doi: 10.1038/nature05485
Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med. 2000;28(12):1735-1744. doi: 10.1016/s0891-5849(00)00231-8
Böyük, A, Banlı O, Gümüş M, Evliyaoğlu O, Demirelli S. Plasma levels of zinc, copper, and ceruloplasmin in patients after undergoing laparoscopic adjustable gastric banding. Biol Trace Elem Res. 2011;143:1282-1288. doi: 10.1007/s12011-011-8965-5
Alissa EM, Bahjri SM, Al-Ama N, Ahmed WH, Ferns GA. High cardiovascular risk in young Saudi males: cardiovascular risk factors, diet and inflammatory markers. Clin Chim Acta. 2006;365(1-2):288-296. doi: 10.1016/j.cca.2005.09.007
González-Jiménez E, Schmidt-Riovalle J, Sinausía L, Carmen Valenza M, Perona JS. Predictive value of ceruloplasmin for metabolic syndrome in adolescents. Biofactors. 2016;42(2):163-170. doi: 10.1002/biof.1258
Chapman AL, Mocatta TJ, Shiva S, et al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J Biol Chem. 2013;288(9):6465-6477. doi: 10.1074/jbc.M112.418970
Taysi S, Polat F, Gul M, Sari RA, Bakan E. Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int. 2002;21(5):200-204. doi: 10.1007/s00296-001-0163-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
